Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271239 | 0.93 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL10320258 | 0.93 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL10318590 | 0.93 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL10317128 | 0.90 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL10317324 | 0.90 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL10317129 | 0.90 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL1271256 | 0.89 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL10317021 | 0.89 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL1270800 | 0.89 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL1271254 | 0.89 | GCK (0.54) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835469-B2 | Substituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2014-09-16 | — | — | US | disclosed |
| EP-2459554-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LTD (IN) | 2013-09-18 | — | — | EP | disclosed |
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
| EP-2459554-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011013141-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | GCK 2/4885KCNH2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.